No price history available for this symbol yet.
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Sector
Drug Manufacturers - Specialty & Generic
Tonghua Dongbao Pharmaceutical Co., Ltd. is a Chinese enterprise primarily engaged in the research, development, manufacturing, and commercialization of pharmaceutical products. These therapeutics are designed to address diabetes and various cardiovascular conditions within the Chinese market. Its operations are structured across two distinct divisions: pharmaceuticals and building materials. The company's extensive pharmaceutical portfolio features prominent insulin analogues, including insulin glargine, insulin aspart, and insulin lispro. Furthermore, it offers a range of antidiabetic medications, oral hypoglycemic drugs, and medical devices such as Gan Shulin pens and blood glucose meters. Tonghua Dongbao also maintains a strategic partnership with Adocia. Established in 1985, the company is headquartered in Tonghua, China.
www.thdb.comNo one on the platform currently holds 600867.SS.
No tracked institution reports a position in 600867.SS as of their last filing.
No one on the platform has traded 600867.SS yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
Consensus does not cover every selected forecast year. Later assumptions are extrapolated from available analyst estimates.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| ROIC % | 21.6% | — | — | — | ||
| Rev. Growth % | 46.7% | 0.4% | ||||
| Profit Margin % | 41.4% | 34.8% | 33.1% | |||
| Free Cash Flow Margin % | 5.8% | 9.4% | 15.2% | |||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $3.3B | +16.9% | $0.32 | $0.27–$0.43 | — | 6 |
| 2027 | $3.7B | +12.1% | $0.39 | $0.32–$0.50 | — | 6 |
| 2028 | $4.2B | +12.8% | $0.43 | $0.38–$0.50 | — | 5 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 5 of the last 8 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2026-08-25 | $0.06 | $0.09 | +50.0% |
| 2026-04-28 | $0.06 | $0.06 | +0.0% |
| 2026-04-19 | $0.04 | $0.01 | -75.0% |
| 2025-10-27 | $0.10 | $0.50 | +400.0% |
| 2025-08-25 | $0.06 | $0.06 | -6.9% |
| 2025-04-29 | $0.05 | $0.01 | -75.2% |
| 2025-04-29 | $0.06 | $0.06 | +0.0% |
| 2024-10-25 | $0.09 | $0.09 | +0.0% |
| Symbol | Price | Today | Mkt cap | P/E |
|---|---|---|---|---|
| 600867.SSTonghua Dongbao Pharmaceutical Co., Ltd. | $7.76 | -0.64% | $15.2B | — |
| 000739.SZApeloa Pharmaceutical Co.,Ltd | $22.37 | -1.37% | $25.9B | — |
| 002019.SZYifan Pharmaceutical Co., Ltd. | $9.24 | -0.75% | $11.2B | — |
| 002432.SZAndon Health Co., Ltd. | $59.36 | +0.27% | $27.7B | — |
| 002755.SZBeijing Aosaikang Pharmaceutical Co., Ltd. |
| $11.26 |
| -1.23% |
| $10.5B |
| — |
| 300009.SZAnhui Anke Biotechnology (Group) Co., Ltd. | $7.96 | -1.36% | $13.3B | — |
| 300357.SZZhejiang Wolwo Bio-Pharmaceutical Co., Ltd. | $18.92 | -0.68% | $9.9B | — |
Source: Financial Modeling Prep · peers by sector/industry